Buparlisib (BKM120, NVP-BKM120)

製品コードS2247

Buparlisib (BKM120, NVP-BKM120)化学構造

分子量(MW):410.39

Buparlisib (BKM120, NVP-BKM120)は1種のセレクティブPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。

サイズ 価格(税別)  
JPY 45152.00
JPY 28220.00
JPY 53120.00
JPY 161020.00

文献中の使用例(37)

カスタマーフィードバック(5)

  • Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 Buparlisib (BKM120, NVP-BKM120)は1種のセレクティブPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。
ターゲット
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外試験

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NHj0fWJEgXSxdH;4bYMhSXO|YYm= MoPQO|IhcA>? NHG4ZY9FVVOR MoKyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= MVSyOFkxODJ4Nh?=
DU145 M4DP[GN6fG:2b4jpZ{BCe3OjeR?= MkjPO|IhcA>? NIi0NJhFVVOR NXWxVVBxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDMT2IyKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFA1OzVizszN NFHvPGIzPDlyMEK2Oi=>
A2780 NUXNS5J1S3m2b4TvfIlkKEG|c3H5 M4\BVlczKGh? MmHDSG1UVw>? NYXGSYo1S3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjN3IN88US=> NWT3bFg4OjR7MECyOlY>
U87MG NWjwfW5QS3m2b4TvfIlkKEG|c3H5 M3\yeVczKGh? NXLINIJsTE2VTx?= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh|ryP NX7XN5V3OjR7MECyOlY>
A2780 NHnzZWxHfW6ldHnvckBCe3OjeR?= NY\3dWc{OSCq M2PNW2ROW09? MXvJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>? MX6yOFkxODJ4Nh?=
DU145 NXnidGtkTnWwY4Tpc44hSXO|YYm= M1PVSFEhcA>? M2\PS2ROW09? NWLFZ4VnUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKESXMUS1JINmdGy|IHjhdoJwemmwZzDMT2IyKG23dHH0bY9vKHerdHigSWM2OCCxZjCwMlA4OyEQvF2= M3nuSFI1QTByMk[2
A2780 NU\l[VlTTnWwY4Tpc44hSXO|YYm= MUixJIg> M2S3WGROW09? NEL4XGlKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDFR|UxKG:oIECuNFc1KM7:TR?= MVuyOFkxODJ4Nh?=
MCF7 NF7oZlJHfW6ldHnvckBCe3OjeR?= MUWxJIg> M4[yNmROW09? M1HBWWlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>? MWGyOFkxODJ4Nh?=
U87MG NFfQb5ZHfW6ldHnvckBCe3OjeR?= MoXXNUBp MYfEUXNQ MUTJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCHQ{WwJI9nKDBwMUOg{txO M1PuWVI1QTByMk[2
A2780 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm3NkBp MmD2SG1UVw>? MV3FR|UxRTBwNUKg{txO MmC0NlQ6ODB{Nk[=
SKMES-1 NFvDWYxEgXSxdH;4bYMhSXO|YYm= MXixJO69VQ>? MkDOO|IhcA>? M4jKVWlv\HWlZYOgZ4VtdCCmZXH0bC=> NHj1VXozPjBzM{OxPC=>
H596 NYjvTplqTnWwY4Tpc44hSXO|YYm= MmjkNUDPxE1? NVrUR3ZNUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= M37EPFI3ODF|M{G4
HCC2450 MUnGeY5kfGmxbjDBd5NigQ>? MnXqNUDPxE1? NFXN[HdKdXCjaYLzJINmdGxiaX72ZZNqd25? MXSyOlAyOzNzOB?=
A549 MV7GeY5kfGmxbjDBd5NigQ>? NXrsUJh7PTByIH7N MVq0PEBp NV\sU|dUTE2VTx?= MXnJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? NYfGXGw2OjV7M{eyPVk>
A549 M{\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxJO69VQ>? NGrS[2w4OiCq NWWwUm5jTE2VTx?= M3XRb2lvcGmkaYTzJINmdGxiZ4Lve5Rp MmjwNlU6Ozd{OUm=
H522 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPxNUDPxE1? MYS3NkBp MWXEUXNQ NWfURplGUW6qaXLpeJMh[2WubDDndo94fGh? MorvNlU6Ozd{OUm=
LNCaP NWCyeoxqTnWwY4Tpc44hSXO|YYm= NVrVXIhQOSEQvF2= NVX6cXFFW3WycILld5NmeyCyLVHLWEBt\X[nbIO= NWXwZ5d{OjV|NkC3PVk>
LNCaP95 NHvk[oJHfW6ldHnvckBCe3OjeR?= MoDONUDPxE1? MYjTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? NGf5[Y8zPTN4MEe5PS=>
HCT-15 MnXrRZBwfG:|aYOgRZN{[Xl? NXv5V|FyOTBizszN M1WyVVQ5KGh? NFzXSXJFVVOR NVjGVYxbUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVE2KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= NGTqPIczPTF3MkK0OS=>
HCT-116 M3nnRmFxd3Sxc3nzJGF{e2G7 MoPkNVAh|ryP MYK0PEBp M2LXTGROW09? NEPrO2RKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M1LL[FI2OTV{MkS1
NCI-H460 NW\wZZliSXCxdH;zbZMhSXO|YYm= M{nrWVExKM7:TR?= M1\m[lQ5KGh? MUnEUXNQ NXXsN41xUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> M{PW[|I2OTV{MkS1
SKOV-3 MmTlRZBwfG:|aYOgRZN{[Xl? MoTENVAh|ryP MYi0PEBp MUXEUXNQ MWPJcoR2[2W|IHHwc5B1d3OrczDpckBUU0:YLUOgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NW\MT4NuOjVzNUKyOFU>
BSY-1 NEXNb2hCeG:2b4Ppd{BCe3OjeR?= MlHzNVAh|ryP MVG0PEBp MV7EUXNQ MXHJcoR2[2W|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v NUL6U2FuOjVzNUKyOFU>
MKN-1 MnrkRZBwfG:|aYOgRZN{[Xl? MUmxNEDPxE1? NF;PPFA1QCCq M17yU2ROW09? MmLDTY5lfWOnczDhdI9xfG:|aYOgbY4hVUuQLUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? MUWyOVE2OjJ2NR?=
NCI-H522 NWfuXnhtSXCxdH;zbZMhSXO|YYm= MVKxNEDPxE1? MUm0PEBp NVjOPHYyTE2VTx?= NIfQc3NKdmS3Y3XzJIFxd3C2b4Ppdy=> MnjUNlUyPTJ{NEW=
OVCAR-3 NUTVWVF3SXCxdH;zbZMhSXO|YYm= M1mzWFExKM7:TR?= MlrvOFghcA>? M3XVT2ROW09? NXTWcmJIUW6mdXPld{BieG:ydH;zbZM> M1;B[|I2OTV{MkS1
HBC-5 NHX5PXpCeG:2b4Ppd{BCe3OjeR?= M4D3UFExKM7:TR?= M1XlRlQ5KGh? NVexcXJUTE2VTx?= MlX3TY5lfWOnczDhdI9xfG:|aYO= NW\qUXNuOjVzNUKyOFU>
RXF-631L MYjBdI91d3OrczDBd5NigQ>? M{\teFExKM7:TR?= NX3OSo9uPDhiaB?= MVrEUXNQ NWLmT2QyUW6mdXPld{BieG:ydH;zbZM> M2r1V|I2OTV{MkS1
MKN-45 NEXEb|FCeG:2b4Ppd{BCe3OjeR?= M{HZUVExKM7:TR?= Mo\kOFghcA>? MmfMSG1UVw>? MYfJcoR2[2W|IHHwc5B1d3Orcx?= NIm0TpEzPTF3MkK0OS=>
BON-1 NFnaXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NSVUxOCCwTR?= NHWzTZcyOCCm MlHwSG1UVw>? NVvlU5ZoUW6qaXLpeJMh[2WubDDndo94fGh? MUiyOVAzPjJ7Mh?=
BON-1 M1uzbGZ2dmO2aX;uJGF{e2G7 NYLqRoh1PTByIH7N NVnBRms{PCCq Mn2xSG1UVw>? NV;pfVFzUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> MoLsNlUxOjZ{OUK=
QGP-1 NYDWeYJWTnWwY4Tpc44hSXO|YYm= M{O3bFUxOCCwTR?= MY[0JIg> M2nmVWROW09? MoqzTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= M{TEZVI2ODJ4Mkmy
Huh7 NWHhUFJRTnWwY4Tpc44hSXO|YYm= MYexJO69VQ>? NFXuW3oyKGh? NW\uNWx1TE2VTx?= MYLJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? NEH6T4QzPTByNESwNy=>
BNL NH7yb|JHfW6ldHnvckBCe3OjeR?= MoPlNUDPxE1? MoDoNUBp MXXEUXNQ MlHMTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3 NUjQRWRnOjVyMES0NFM>
MDA-MB-175 M334V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\rNUDPxE1? MkXKOUBl NWS4RnRNTE2VTx?= MmnvTWM2ODxzIN88US=> MYCyOFg4QTd7Nh?=
MDA-MB-134 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{iwe|Eh|ryP NYjvTnNsPSCm NY\0c3pxTE2VTx?= NHvDTWNKSzVyPEGg{txO Mlu1NlQ5Pzl5OU[=
HCC1500 NUiw[nVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XFdFEh|ryP NVXtXmc2PSCm M4mzWGROW09? M4jhZWlEPTB:MTFOwG0> NXryNXFIOjR6N{m3PVY>
EFM-19 M2W2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjrWmJwOSEQvF2= MnH5OUBl M3[3R2ROW09? NXrVTZRSUUN3MEyxJO69VQ>? NUHtbYtYOjR6N{m3PVY>
ZR-75-30 NF3aUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4dGVyOSEQvF2= MX:1JIQ> NGPjeYdFVVOR NInuTZJKSzVyPEGg{txO NYS2[3ZMOjR6N{m3PVY>
MDA-MB-361 NY\5VoFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki2NUDPxE1? NFHrV5U2KGR? MkDISG1UVw>? NGn6V25KSzVyPEGg{txO NH\0NpczPDh5OUe5Oi=>
T-47D NVfsR3J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLvdZBrOSEQvF2= NHPJe|M2KGR? NGO0UpFFVVOR NEXuNplKSzVyPEGg{txO NYXHR2llOjR6N{m3PVY>
SK-BR-3 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHQT2IzOSEQvF2= NEjHb2Y2KGR? MnqzSG1UVw>? MkHITWM2ODxzIN88US=> NX\q[VZ3OjR6N{m3PVY>
UACC-732 M2LHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxJO69VQ>? MWW1JIQ> MVfEUXNQ NYjn[ZRtUUN3MEyxJO69VQ>? MYqyOFg4QTd7Nh?=
BT-474 NFrtc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTPNUDPxE1? M2[wZ|Uh\A>? MYXEUXNQ NYLiT2I3UUN3MEyxJO69VQ>? M{P5blI1QDd7N{m2
HCC202 NIDlNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j1d|Eh|ryP M3r1XVUh\A>? NV3ROY1MTE2VTx?= MlXnTWM2ODxzIN88US=> NHnjTmozPDh5OUe5Oi=>
MCF7 NUPM[XdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXtW3MyKM7:TR?= Mm\5OUBl MXfEUXNQ MXnJR|UxRDFizszN NUK1ZlNROjR6N{m3PVY>
MDA-MB-415 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S5OFEh|ryP NVzwTGt6PSCm M1XQRmROW09? NFG5cI9KSzVyPEGg{txO MknXNlQ5Pzl5OU[=
MDA-MB-453 M3Gxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6xJO69VQ>? MXu1JIQ> NEjnZVFFVVOR NUjPZYxbUUN3MEyxJO69VQ>? M2TyO|I1QDd7N{m2
ZR-75-1 NVLuUVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILzNVUyKM7:TR?= MYO1JIQ> MoXFSG1UVw>? MmLrTWM2ODxzIN88US=> MXeyOFg4QTd7Nh?=
HCC38 NWrrNJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rnUlEh|ryP NFnFTm82KGR? MYDEUXNQ MlXZTWM2ODxzIN88US=> NF64[XczPDh5OUe5Oi=>
HCC1419 NH\DeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixJO69VQ>? NI\UfHI2KGR? M4LqRmROW09? MlnwTWM2ODxzIN88US=> MUSyOFg4QTd7Nh?=
UACC-812 NGPHSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHVNUDPxE1? M3zpOFUh\A>? MnnZSG1UVw>? NF6yWGdKSzVyPEGg{txO MU[yOFg4QTd7Nh?=
HCC1187 NHTEUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvJNUDPxE1? Mnu0OUBl NHfTRlRFVVOR NVfLOmV[UUN3MEyxJO69VQ>? M2\2dVI1QDd7N{m2
KPL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrLcY8yKM7:TR?= NYPzeHdjPSCm NXraUWs2TE2VTx?= MmfHTWM2ODxzIN88US=> MWmyOFg4QTd7Nh?=
SUM-225 NWn5Z2xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGxJO69VQ>? NWDISnp7PSCm MoTMSG1UVw>? MUPJR|UxRDFizszN NHzQdnQzPDh5OUe5Oi=>
EFM-192A Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxJO69VQ>? MWC1JIQ> NIPabnVFVVOR M4P6[GlEPTB:MTFOwG0> NIS3VpUzPDh5OUe5Oi=>
JIMT-1 M1T1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jhWFEh|ryP MYS1JIQ> NGHyWGxFVVOR MVLJR|UxRDFizszN NFXaVmkzPDh5OUe5Oi=>
HCC1143 NXTnTlY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Pp[lEh|ryP MWK1JIQ> NWLxfI9qTE2VTx?= M1q4TWlEPTB:MTFOwG0> MYiyOFg4QTd7Nh?=
HCC2218 NXXCcnF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxJO69VQ>? MmTROUBl MXrEUXNQ NHfYTnRKSzVyPEGg{txO NYDzUJF6OjR6N{m3PVY>
MDA-MB-468 NIDSOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxJO69VQ>? MXO1JIQ> NYC5dG9GTE2VTx?= M1[2ZWlEPTB:MTFOwG0> NETmc4UzPDh5OUe5Oi=>
BT-20 NHLQS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13TOVEh|ryP MmTnOUBl NWOyeZdnTE2VTx?= MlvLTWM2ODxzIN88US=> M4DNfVI1QDd7N{m2
MDA-MB-435 M1zr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;wNlEh|ryP MUS1JIQ> M{npNmROW09? MVzJR|UxRDFizszN NWHBUIdOOjR6N{m3PVY>
BT-549 NHLPVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELxcFYyKM7:TR?= MVK1JIQ> M4XCU2ROW09? MoWwTWM2ODxzIN88US=> MlexNlQ5Pzl5OU[=
HCC1806 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrzNUDPxE1? NEfoTno2KGR? MljKSG1UVw>? MoriTWM2ODxzIN88US=> MVOyOFg4QTd7Nh?=
HCC1937 NYHCPXhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zbJdJOSEQvF2= NFPLT4E2KGR? MVrEUXNQ MkfXTWM2ODxzIN88US=> NVHkepN6OjR6N{m3PVY>
Hs578T MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETDbJQyKM7:TR?= NXjX[nQyPSCm NViwfplLTE2VTx?= NYXJSlBiUUN3MEyxJO69VQ>? NVvsUoYxOjR6N{m3PVY>
LN18 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqyNEDPxE1? Mlr6O|IhcA>? MU\EUXNQ NYDofFNWUUN3MEy1JO69VQ>? M4P6fFI1PzRzMEe0
LN229 NYH2NGxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrQOIwzOCEQvF2= M2fMUVczKGh? MlPMSG1UVw>? NITTXndKSzVyPEWg{txO NEHwfYozPDd2MUC3OC=>
LNZ308 NV6wRo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M335T|IxKM7:TR?= Ml74O|IhcA>? NVjhU41DTE2VTx?= NF\yb5BKSzVyPEWg{txO NVTIdYs5OjR5NEGwO|Q>
T98G NUDkfHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPNN|dJOjBizszN MU[3NkBp MWLEUXNQ MUDJR|UxRDVizszN MlPsNlQ4PDFyN{S=
U87 NUfBdFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:yNEDPxE1? MY[3NkBp Ml3SSG1UVw>? MWHJR|UxRDVizszN M4XtTVI1PzRzMEe0
LN18 MYHGeY5kfGmxbjDBd5NigQ>? NGLBNIM2KM7:TR?= MoH3NlQhcA>? M3\YZ2ROW09? M1;N[2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? M3WxRVI1PzRzMEe0
LNZ308 MnHUSpVv[3Srb36gRZN{[Xl? NG\3eWE2KM7:TR?= NU\u[HBIOjRiaB?= MVfEUXNQ MnHaTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NFWyeWEzPDd2MUC3OC=>
Saos-2 MnzESpVv[3Srb36gRZN{[Xl? NH3VNXg2OCEQvF2= MkPGOFghcA>? NGPGeYRKdmirYnn0d{Bk\WyuIHnueoF{cW:w NXfiSZRrOjR5Mke2OlA>
MG-63 NV;yOHBOTnWwY4Tpc44hSXO|YYm= NGDxNIc2OCEQvF2= NH3reGs1QCCq M3mzTWlvcGmkaYTzJINmdGxiaX72ZZNqd25? M3X4SVI1PzJ5Nk[w
SJSA-1 NVHmW|FGTnWwY4Tpc44hSXO|YYm= NWf4SFJVPTBizszN NH;yNIo1QCCq NXviW|FOUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M3roV|I1PzJ5Nk[w
Saos-2 NVLVOoc3TnWwY4Tpc44hSXO|YYm= NX7FXWZoPTBizszN NXL6cW1RPDhiaB?= NEG5WGRKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MX[yOFczPzZ4MB?=
MG-63 NGTTVIxHfW6ldHnvckBCe3OjeR?= NFnJS3A2OCEQvF2= MnXjOFghcA>? NF;hVGZKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NXXzXVlHOjR5Mke2OlA>
SJSA-1 NH;Gd2RHfW6ldHnvckBCe3OjeR?= MWm1NEDPxE1? M1LzfVQ5KGh? M4LmfWlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NI\QNVQzPDd{N{[2NC=>
Saos-2 M4PteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[2U2hGPTBizszN NG\0VVU1QCCq MVjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MYWyOFczPzZ4MB?=
MG-63 M{nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm1NEDPxE1? NFGyWIE1QCCq NE\4VJZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NIfpfY0zPDd{N{[2NC=>
SJSA-1 M2PXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy1NEDPxE1? Mnr4OFghcA>? MoLlTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NHfTXHMzPDd{N{[2NC=>
FaDu NVzG[|Z1TnWwY4Tpc44hSXO|YYm= Ml7hOUDPxE1? MoXTNlQhcA>? M1n0V2ROW09? NX;zdYhOWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> MYOyOFY{OTF2Nx?=
EMT6 M37HemZ2dmO2aX;uJGF{e2G7 M2nyUVUh|ryP NFvPRpUzPCCq NE\CXHVFVVOR MUjS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NFvYVFEzPDZ|MUG0Oy=>
HCT116 NUXYNoM6TnWwY4Tpc44hSXO|YYm= NYfGWmlKPSEQvF2= MWWyOEBp MV\EUXNQ NU\He4xsWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NEDa[HozPDZ|MUG0Oy=>
U87 NHqzeXFHfW6ldHnvckBCe3OjeR?= NF;tfIQ2KM7:TR?= Mn\lNlQhcA>? NUCySHVQTE2VTx?= M1HGR3Jm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NEm2do8zPDZ|MUG0Oy=>
GBM M2\GeGFxd3C2b4Ppd{BCe3OjeR?= NX3L[mdtOs7:TR?= M3T0cVQ5cA>? NYPxcIptTE2VTx?= MnvwbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> M1foelI1PTByNEmy
BON NUnKZoZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULJTGlJOS13zszN NGLXRWg4Omh? NILtUY9l\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v NEO2WlEzPDR2M{WyNy=>
BON MXXBdI9xfG:|aYOgRZN{[Xl? NHvyPZUyNTYQvF2= NWPpcpJNOjSq M4jvU4lv[3KnYYPld{BieG:ydH;zbZM> M2P4dVI1PDR|NUKz
H1975 NULJTWdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;HNE4{NTlwNt88US=> NGHL[YU4Omh? MW\EUXNQ M336ZWlEPTB;MT6zPFXPxE1? NYr1c4VVOjR|M{e4OFY>
H1975 MU\BdI9xfG:|aYOgRZN{[Xl? M13sUFLPxE1? NGTIN3czPGh? NFn5U3ZFVVOR NYrqZ|FLcW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? NFnRXHMzPDN|N{i0Oi=>
T-ALL MUfBdI9xfG:|aYOgRZN{[Xl? M4PWUIJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= NWDZXYlGOjRib4KgOFhp MXzEUXNQ M1zCOoFn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz NELvfHozPDNzMEezOi=>
BCR-ABL NGrU[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMlI2NTFyzszN NXj1TG5rPGR? M4DzeZNq\26rZnnjZY51dHliaX7obYJqfCClZXzsJJBzd2yrZnXyZZRqd25? MVSyOFI1PDZzMh?=
LC-1/SQSF M4TMbWZ2dmO2aX;uJGF{e2G7 MWiz{txO NInHXGEzPGh? NV;JNos5TE2VTx?= MXHk[YNz\WG|ZTDOVmYzKHC{b4TlbY4hdGW4ZXy= NXq5fIJWOjN7OECwPVM>
Primary CLL cells NEjZcHVCeG:ydH;zbZMhSXO|YYm= NXHpW5dLOS1zMN88US=> MWK0PIg> MoHKbY5lfWOnczDhdI9xfG:|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=> MYmyN|g2ODhyNx?=
Primary CLL cells NV3PPZZFU2mwYYPlJGF{e2G7 MmezNu69VQ>? NFLoWok{OG2rbh?= Mn7M[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? M3zqXFI{QDVyOEC3
Primary CLL cells M3HiR2N6fG:2b4jpZ{BCe3OjeR?= NXPvdmtxOs7:TR?= MY[yOIg> MXTpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 NFLCT|gzOzh3MEiwOy=>
human NSCLC cell lines MVfBdI9xfG:|aYOgRZN{[Xl? M2q2PFAvOTJ3LUVOwG0> NFHCeGUzPGh? MkfnSG1UVw>? NEnnRpNKSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=> NWj4cWx{OjN3NkK0O|I>
human HCC cell lines M4TFOmNmdGxidnnhZoltcXS7IHHzd4F6 MXGwMlAxPS1zzszN NYHQXXBZPDiq NXK1Nmt4UUN3ME2x{txO MUSyN|Q5QTl7OR?=
Huh7 MYLLbY5ie2ViQYPzZZk> M3foeVHPxE1? M4SxcFQ5cA>? MkjRd4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0 NYj4bHRwOjN2OEm5PVk>
SK-HEP1 M1XPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxMVIx|ryP NX:5VI1WPzKq MW\EUXNQ MmDjTWM2OO,:nEJOwG0> NYriTJNyOjN2N{mxN|Y>
786-0 M{XSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXObYoyNTJyzszN M3GzbVczcA>? M{DKOGROW09? NGjBW3FKSzVy78{cNe69VQ>? M13UO|I{PDd7MUO2
JVM2 NUSxdVdjS3m2b4TvfIlkcXS7IHHzd4F6 MX2wMlIuOjEQvF2= MmLuO|Jp NV3iO2tSTE2VTx?= NUPrRY55UUN3ME2wMlnPxE1? NI[5XoczOzJ|OE[zPS=>
EHEB MkPCR5l1d3SxeHnjbZR6KGG|c3H5 MmrBNE4zNTJyzszN MV63Nog> NV3USGo2TE2VTx?= NXyyXoVMUUN3ME2wMlfPxE1? MUCyN|I{QDZ|OR?=
MEC2 MkXQR5l1d3SxeHnjbZR6KGG|c3H5 NGrvdZUxNjJvMkFOwG0> M3XJVVczcA>? NXGzRnB5TE2VTx?= NFrlUmxKSzVyPUCuO:69VQ>? MXGyN|I{QDZ|OR?=
primary B-CLL lymphocytes NHnL[FZCeG:ydH;zbZMhSXO|YYm= M3m0RWlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? M3HsVlI1cA>? MVnEUXNQ NEj5cYVKSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ M1XFc|I{OjN6NkO5
primary B-CLL lymphocytes MoXET4lv[XOnIFHzd4F6 NWLXWnFPUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= M1rYdlI1cA>? NXnGPYVicW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44> NGDpNG4zOzJ|OE[zPS=>
human NSCLC NFjWS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;q[FAvPS1{zszN NVvFSWRZPzKq MV;JR|UxRTIQvF2= Mm\JNlI4QDF|OUO=
human NSCLC NEG3e4hMcW6jc3WgRZN{[Xl? M361elHPxE1? MkXqNlRp NUfRfWVWcW6qaXLpeJMhfGinIFHreE9uXE:UIIPp[45idGmwZzDwZZRpf2G7IHH0JFNpKGGodHXyJJRz\WG2bXXueC=> MkTLNlI4QDF|OUO=
Y1 cell line M3PMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;COm5wOC5zzszNM|HPxE1? MkT3NlRp Ml;zSG1UVw>? NV75PYFOcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= M4TxUFIzPjl{OUC0
PIK3CA-mutant MCF7 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HNeWdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P MVq3Nog> NX64dllDT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= MUSyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 M1K4OWtqdmG|ZTDBd5NigQ>? MULJR|UxRTFzNNMxN45O NYL5dmp3PzKq MVPJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| NUDTSGFTOjJ4NUO5Olc>
MCF7-myr-Akt M2flXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Sz[mdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P MXe3Nog> Mm[yS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? NFvweVczOjZ3M{m2Oy=>
colon cancer cell lines NHHnZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\JbJo{OC1zMN88US=> NU[4fmo6PzKq NVTvcG96TE2VTx?= MWHJR|UxRTIQvF2= M3rOW|IzPTR|OEW3
gastric cancer cell lines MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMVEx|ryP MlrXO|Jp NVvmcod7TE2VTx?= MVvJR|UxRTJvNd88US=> NEG2c5gzOjV2M{i1Oy=>
HCT-116/HT-29/MKN-45 MXLBdI9xfG:|aYOgRZN{[Xl? MkX5Nu69VQ>? NIPSVHI1QGh? NGL2c3R{cGmodDDpckBIOiCyaHHz[S=> NWPid5pWOjJ3NEO4OVc>
HT-29 and HCT-116 NYfhSXFPS2G|cHHz[UBie3OjeR?= NGDjWHA2|ryP NXeyfGVpOjSq MVrpcoR2[2W|IHPhd5Bie2ViYXP0bZZqfHl? NXLDSZFzOjJ3NEO4OVc>
MM cell lines MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fTPVEx|ryP NVXIOFZoOjSq NYq5enk6TE2VTx?= MmXtTWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm NHj0S|QzOjJyN{S4OS=>
ARP-1 MVfBdI9xfG:|aYOgRZN{[Xl? MnOyNVDPxE1? MWOyOIg> MWHEUXNQ NFLPUlNqdmS3Y3XzJG1OKGOnbHygZZBweHSxc3nzJJRpem:3Z3igZ4F{eGG|ZTDhZ5RqfmG2aX;u NUW4WHloOjJ{MEe0PFU>
SNU-601 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHCO|Jp MnXWSG1UVw>? MY\JR|UxRTBwOEG2xtExNjB4M988US=> M2rQdlIzOTV7OEG0
SNU-1 NE\YZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHxO|Jp NVTnWYU4TE2VTx?= NVfNc3ZbUUN3ME2xMlA5OsLzMD6wNljPxE1? NXvLW4ZnOjJzNUm4NVQ>
SNU-668 NXmxc|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX23Nog> NH7NS4VFVVOR MUTJR|UxRTFwNUe5xtExNjB5NN88US=> Mor2NlIyPTl6MUS=
AGS M2rNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33qOlczcA>? Mm\xSG1UVw>? NYHLZlF3UUN3ME2xMlcyPMLzMD6xNVfPxE1? M3zwblIzOTV7OEG0
SNU-216 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[3Nog> MVfEUXNQ MV3JR|UxRTJwNkmyxtExNjB6Mt88US=> M3flWlIzOTV7OEG0
SNU-5 M1qwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\QR21LPzKq NH3PdYlFVVOR M1q1eGlEPTB;MT6zOVHDuTBwMEmx{txO MoLNNlIyPTl6MUS=
SNU-638 NYL0V5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjsT4c4Omh? NFHHTYJFVVOR M1\zXGlEPTB;Mj6yPFLDuTBwMEWz{txO MoDoNlIyPTl6MUS=
SNU-16 NWDq[mlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrTO2Y4PzKq NYPsS41KTE2VTx?= M{nnZ2lEPTB;MT61O|PDuTBwMECx{txO NIr6SHUzOjF3OUixOC=>
SNU-484 NXmyXZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJO|Jp M{P0PWROW09? M3q0eGlEPTB;MT63NljDuTBwMES1{txO NV\YfYRlOjJzNUm4NVQ>
SNU-620 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCO|Jp NF7zZWhFVVOR NXTBUoNxUUN3ME2yMlk{QcLzMD6wNFHPxE1? MnTSNlIyPTl6MUS=
SNU-719 NELBcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i2VFczcA>? M{PsfGROW09? NHL4OGFKSzVyPUOuNFM4yrFyLkCzNu69VQ>? NWTBVlV1OjJzNUm4NVQ>
glioma cell lines NFjNT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3Nog> M1r1b2lEPTB;MT2y{txO Mnz1NlIxPjVyOEC=
U87 MkTCRZBweHSxc3nzJGF{e2G7 NX;YVWd4Os7:TR?= M1;KR|czcA>? MnTWbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO= MmD2NlIxPjVyOEC=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
細胞試験: [1]
+ 展開
  • 細胞株: A2780 cells.
  • 濃度: 0-6.6 μM
  • 反応時間: 3 days.
  • 実験の流れ: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: U87MG and A2780 xenografts are established in female nu/nu mice.
  • 製剤: In 15% Captisol.
  • 投薬量: ~60 mg/kg.
  • 投与方法: Dosed orally daily (q.d.).
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 順序で溶剤を入れること:
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 410.39
化学式

C18H21F3N6O2

CAS No. 944396-07-0
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Completed c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9, 2014 Phase 1|Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT02756247 Recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active, not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: Buparlisib (BKM120, NVP-BKM120)を買う | Buparlisib (BKM120, NVP-BKM120) ic50 | Buparlisib (BKM120, NVP-BKM120)供給者 | Buparlisib (BKM120, NVP-BKM120)を購入する | Buparlisib (BKM120, NVP-BKM120)費用 | Buparlisib (BKM120, NVP-BKM120)生産者 | オーダーBuparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)化学構造 | Buparlisib (BKM120, NVP-BKM120)分子量 | Buparlisib (BKM120, NVP-BKM120)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID